VIDEO: Pembrolizumab regimen may benefit OS in triple-negative breast cancer

BySavannah Demko

ByNancy U. Lin, MD

Fact checked byMindy Valcarcel, MS

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

The study showed that neoadjuvant pembrolizumab (Keytruda, Merck) plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in OS compared with neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.

“These are the first overall survival data that we’ve seen from KEYNOTE-522,” Lin said. “I think that they continue to support the use of pembrolizumab with chemotherapy in the preoperative setting in patients with triple-negative breast cancer.”

Reference:

Schmid P, et al. Abstract LBA4. Presented at: European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interviews

Disclosures: Lin reports receiving institutional research support, consulting honoraria, travel and/or royalties from AstraZeneca, Artera Inc., Blueprint Medicines, Daichii-Sankyo, Eisai, Genentech, Janssen, Olema Pharmaceuticals, Pfizer, Merck, Seagen, Stemline/Menarini, Up To Date and Zion Pharmaceuticals.

Take Homes in Breast Cancer

Read more

VIDEO: Pembrolizumab regimen may benefit OS in triple-negative breast cancer

Reference:

Related Content